Full-Time

Specialist Data Architect

Updated on 9/6/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's

Category
Data & Analytics (1)
Required Skills
Apache Spark
Data Modeling
Data Governance
Databricks
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A Master’s degree with 4–6 years of experience in Computer Science, IT, or a related field, or a Bachelor’s degree with 6–8 years of experience in Computer Science, IT, or a related field, or a Diploma with 10–12 years of experience in Computer Science, IT, or a related field.
  • Proficiency in creating conceptual, logical, and physical data models to represent information structures.
  • Ability to interview and communicate with business subject matter experts to develop data models useful for their analysis needs.
  • Knowledge of metadata standards, taxonomies, and ontologies to ensure data consistency and quality.
  • Hands-on experience with big data technologies and platforms such as Databricks and Apache Spark, including PySpark and SparkSQL, and performance tuning on big data processing.
  • Experience implementing data testing and data quality strategies.
  • Excellent critical-thinking and problem-solving skills.
  • Strong communication and collaboration skills.
Responsibilities
  • Develop and maintain conceptual, logical, and physical data models to support business needs.
  • Contribute to and enforce data standards, governance policies, and best practices.
  • Design and manage metadata structures to enhance information retrieval and usability.
  • Maintain comprehensive documentation of the architecture, including principles, standards, and models.
  • Evaluate and recommend technologies and tools that best fit solution requirements.
  • Drive continuous improvement in the architecture by identifying opportunities for innovation and efficiency.
Desired Qualifications
  • Experience with graph technologies such as Stardog, AllegroGraph, and MarkLogic.
  • Databricks certification is desired.
  • Demonstrated awareness of how to function in a team setting.
  • Demonstrated awareness of presentation skills.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10%, and management raised full-year guidance again.
  • Repatha sales jumped 37% in Q2 2026 on stronger cardiology and primary-care demand.
  • Amgen approved IMDYLLTRA in Europe and opened a 2027 Hyderabad innovation center.

What critics are saying

  • FDA scrutiny threatens Tavneos withdrawal after the NEJM retraction and data-alteration probe.
  • Prolia sales fell 32% in Q2 2026 as biosimilar competition intensifies.
  • MariTide failure would leave Amgen dependent on aging brands and biosimilars after 2027.

What makes Amgen unique

  • Amgen sells multiple billion-dollar medicines, reducing dependence on any single franchise.
  • Repatha now shows hard cardiovascular mortality benefit, strengthening payer and physician adoption.
  • MariTide's monthly dosing targets a convenience gap versus weekly GLP-1 incumbents.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.